A new cancer drug has been approved for use in Scotland, which will mean some of those diagnosed with the condition will not have to undergo chemotherapy.
Venetoclax has been given the go-ahead for patients with chronic lymphocytic leukaemia (CLL) by the Scottish Medicines Consortium after it was found it could offer adults with the condition a better chance at survival when used with obinutuzumab.
It is among six medicines approved for use in the NHS.
